U.S. Patent and Trac

PTO-1390 (Rev. 12-2004) of for use through 3/31/2007. OMB 0651-0021 office; U.S. DEPARTMENT OF COMMERCE s it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

ATTTORNE DOCKET NUMBER ON/4-32548A

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/IB03/02794 17 June 2003 (17.06.03) 28 June 2002 (28.06.02) TITLE OF INVENTION 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL}-BENZAMIDE FOR TREATING PULMONARY FIBROSIS APPLICANT(S) FOR DO/EO/US JOSEPH ALEXANDER LASKY Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). 5. **X** A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. 8. 🗀 An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes of the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. 🔲 An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. 🗶 A preliminary amendment. 14. 🗶 An Application Data Sheet under 37 CFR 1.76. A substitute specification. A power of attorney and/or change of address letter. 17. **[** A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. 🗀 A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. Other items or information: Unexecuted Declaration and Power of Attorney

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mall Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2 FILING BY "EXPRESS MAIL" **UNDER 37 CFR 1.10**

1 443788285 US Express Mail Label Number



PTO-1390 (Rev. 12-2004)
An for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trade.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICA	ION NO. (if known, see	27 CER 1-5)	INTERNATIONAL AP	PLICATION NO.	ATTORNEY'S DOC	KET NUMBER
1	100 NO. (if known, see 10 / 518	988	PCT/IB03/	02794	ON/4-32	548A
21. The following fees are submitted:						
a) Basic national fee\$300.00					\$ 300.00	
b) Examination fee\$200.00					\$ 200.00	
X c) Search fee\$500.00					\$ 500.00	ļ
TOTAL OF ABOVE CALCULATIONS = \$1000.00					\$ 1,000.00	Į.
	ee for specification and d		1			
	mputer program listing fill i0 sheets of paper or frac		ŀ			
				1		
Total Sheets	Extra sneets		nber of each additional 50 or fraction RATE ereof (round up to a whole number)			
- 100 =	/50 =		0	× \$250.00	\$ 0.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest				0.00	 	
	date (37 CFR 1.492(e)).	\$ 0.00				
CLAIMS NUMBER FIL		LED	NUMBER EXTRA	RATE	\$	
Total claims		9 - 20 =	0	x \$50.00	\$ 0.00	<u> </u>
Independent claims		3 - 3 =	0	x \$200.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00					\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =					\$ 1,000.00	
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.					\$	
SUBTOTAL =					\$ 1,000.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					\$	
TOTAL NATIONAL FEE =					\$ 1,000.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property					\$	
TOTAL FEES ENCLOSED =					\$ 1,000.00	
					Amount to be refunded:	\$
					Amount to be	\$
		charged:				
a. A check in the amount of \$ to cover the above fees is enclosed.						
b. Please charge my Deposit Account No. 19-0134 in the amount of \$ 1,000.00 to cover the above fees. A duplicate copy of this sheet is enclosed.						
c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No. 19-0134 Account No. 19-0134 Account No. 19-0134						
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.						
SEND ALL COR	RRESPONDENCE TO:		A			
Novartis SIGNATURE					y y w	
Corporate Intellectual Property Oona A.					Jacksón	
One Health Plaza, Bldg. 104						
48,152					ION AUTABED	
EGSI HONOVEI, NJ U7936-1000 REGISTRATIO					ION NUMBER	